ranQ
ranQ
ranQ
DirectoryIndustriesPlacesKnowledgeComparisonsSoon
Sign inCheck visibility
ranQHSG Startup LabelRecognised by the
HSG Startup Label

The leading AI company directory, built to boost AI visibility.

DEENFRIT
Product
  • Pricing
  • Directory
  • Industries
  • Trust Score
Company
  • About
  • Contact
  • Legal
© 2026 cohaga AG · All Rights Reserved · St. Gallen, Switzerland · Imprint745,701 companies indexed · Last updated: today
DirectoryBusiness & Technical ServicesResearch & DevelopmentBaselSynendos Therapeutics AG
Synendos Therapeutics AG Logo
Verified· 3 sourcesTrust Score
Summary

About the company

The core activity of Synendos Therapeutics AG is the development of pharmaceuticals, particularly the research and development of active ingredients and medicines in various therapeutic areas, including clinical trials and approval. The company focuses on the development of medicines for various diseases, including neurological disorders, and offers services in the fields of medicinal chemistry, pharmacology, clinical research and development.

AI-generated
Offering

Products & services

Industry:Research & DevelopmentPharmaceutical Industry
LeadhubOutbound Leads by COHAGA

Looking for direct email addresses and phone numbers?

Leadhub delivers verified contact details and decision-makers from over 750,000 Swiss companies — management, procurement, marketing, HR.

Discover Leadhub
4.1/5

Synendos Therapeutics AG

✓ Offered4
Development of SERI therapeutics
Development of Selective Endocannabinoid Reuptake Inhibitors (SERIs) for the treatment of neuropsychiatric disorders; first-in-class small molecules with a new mechanism of action.
Clinical development of SYT-510
Clinical development of the lead candidate SYT-510, including completed preclinical work and Phase 1 studies, as well as a planned Phase 2a study in generalized anxiety disorder.
Development of additional ECS modulators
Development of additional selective endocannabinoid reuptake inhibitors and alternative ECS modulators in an early development phase for neuropsychiatric disorders.
Research on endocannabinoid system therapies
Research on the endocannabinoid system as a new therapeutic approach to restore brain function in neuropsychiatric and other CNS disorders.
Trust & reputation

ranQ Trust Score of Synendos Therapeutics AG: 4.1 out of 5.0

Trust Score4.1/ 5.0

High

x

Data basis 58% · As of October 2026

Without public customer reviews the score stays capped.

Synendos Therapeutics AG has no value in the Reputation area of the ranQ Trust Score because no data is available. The area carries 42% of the weighting and drops out of the calculation for this profile; it does not lower the score, only the reported data basis.
x
CriterionValueWeight
  • Review quality: No data point — the criterion is taken out of the weighting and does not lower the score.—24%
  • Review volume: No data point — the criterion is taken out of the weighting and does not lower the score.—10%
  • Review recency: No data point — the criterion is taken out of the weighting and does not lower the score.—8%
Synendos Therapeutics AG scores 81.6 out of 100 points in the Substance area of the ranQ Trust Score. This area carries 28% of the weighting.
x
CriterionValueWeight
  • Establishment: Years since founding or brand launch, logarithmic. The maximum is reached at 15 years.75.012%
  • Company size: The headcount band, researched by ranQ or stated by the company. It is scored in steps rather than by head count, because the data only provides bands.82.07%
Synendos Therapeutics AG scores 85.0 out of 100 points in the Identity area of the ranQ Trust Score. This area carries 22% of the weighting.
x
CriterionValueWeight
  • Verification: Official register entry (commercial register with UID or professional-body record, 55 points), confirmed domain (20 points) and confirmed ranQ profile (up to 25 points, depending on completeness).85.022%
Synendos Therapeutics AG scores 54.8 out of 100 points in the Visibility area of the ranQ Trust Score. This area carries 8% of the weighting.
x
CriterionValueWeight
  • Website authority: Ahrefs' Domain Rating measures, on a scale of 0 to 100, how strongly a website is linked from other websites. For Swiss SMEs the range up to 40 is typical; the maximum is reached at 35.82.94%
  • Media authority: Quality and number of editorial mentions, weighted by the importance of the source, plus the recency of the latest high-quality mention.26.74%
Qualifications+0.00

Synendos Therapeutics AG reaches a ranQ Trust Score of 4.1 out of 5.0 — rated «High». No public customer reviews are available for this provider; the rating is based on the remaining criteria. The data basis is 58%, so the score is backed by part of the criteria. As of October 2026.

The Trust Score cannot be bought and is calculated from publicly verifiable data.

Press

Media

August 14, 2025Media
Four startups welcome new leaders to accelerate growth
startupticker.ch
November 12, 2020Media
Synendos Therapeutics secures CHF 20 million
startupticker.ch

Knowledge

No knowledge articles yet

Once Synendos Therapeutics AG has claimed this profile, we'll publish editorial articles and case studies here together.

Get started
Comparisons

Synendos Therapeutics AG in comparison

Soon

Industry comparisons are coming soon

We're preparing industry comparisons that rank Synendos Therapeutics AG by reviews, experience and specialisations.

Is this your company?

Claim the company profile of Synendos Therapeutics AG to make its contact details visible. With a plan we additionally create and publish industry comparisons, articles and much more.

Secure profile

Location

Barfüsserplatz 3
4051 Basel

At a glance

Legal form
Corporation
UID
CHE-145.781.587
Founded
2019 · 7 years
Last commercial register change
July 31, 2025
Employees
21 to 50
Legal form: Graded by liability and disclosure. The weight is kept small: a sole proprietorship is not a dubious company, it is just liable differently.
100.0
6%
  • Branch offices: Branch offices linked in the commercial register. Having none is normal and costs no points.70.03%
    • Full methodology

    Similar companies

    IP
    Ironwood Pharmaceuticals GmbH
    Basel
    PI
    PAREXEL International (CH) AG
    Basel
    IS
    Immunovant Sciences GmbH
    Basel
    SC
    St. Clara Forschung AG
    Basel
    3B
    3T Biosciences Europe GmbH
    Basel
    IM
    Inari Medical Europe GmbH
    Basel
    SB
    SOTIO Biotech AG
    Basel
    PA
    Prosalix AG
    Basel